CHEN Xiaoguang
Principal Investigator
Dr. Chen Xiaoguang, Professor, is Chair of the Department of Pharmacology. Dr. Chen obtained her Ph.D. degree in pharmacology from Peking Union Medical College in 1995 and worked as a visiting professor at the Osaka University in Japan (1996), as a visiting scholar at the Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois in Switzerland (1997), and the Henry Ford Hospital in the USA (2001). Since joining the Institute of Materia Medica in 1995, Dr. Chen has focused her research on cancer molecular pharmacology and anti-cancer drug development. Her research interests include novel anti-cancer drug targets, signaling pathway inhibitors, and the development of small-molecule agonists/antagonists for cancer immunotherapy. Dr. Chen has authored more than 100 research papers, edited 3 textbooks for graduate students, and has been awarded 34 international/national patents. As the Principal Investigator, Dr. Chen has completed multiple projects on the development of novel drugs, and successfully sold six Type-I drugs for commercialization.
Dr. Chen is one of the leaders in the field of small-molecule drugs for cancer immunotherapy. She is interested in molecular pharmacological research and has developed novel antitumor drugs based on novel molecular targets, immunotherapy-related checkpoint inhibitors and metabolism checkpoint inhibitors including PARP1/2, PI3K, STAT3, HSP90, PD1/PD-L1, IOO1/TDO, LAG3, ACAT1, etc .
1. A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models. Acta Pharmaceutica Sinica B. 2021 online
2. Design, synthesis, and biological evaluation of a novel photocaged PI3K inhibitor toward precise cancer treatment. J. Med. Chem. 2021 online.
3. A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models. Acta Pharmaceutica Sinica B. 2020, 10(2):276-288.
4. Design, synthesis, and biological evaluation of amidobenzimidazole derivatives as Stimulator of Interferon Genes (STING) receptor agonists. J Med Chem. 2020, 63(1):260-282.
5. Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors. Bioorg Med Chem. 2020, 29:115890.
6. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity. Cancer Letters. 2020, 495:22–32.
7. Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors. Eur J Med Chem. 2020, 188:111985.
8. Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies. Eur J Med Chem. 2020, 190:112079.
9. Prediction value of serum NGAL in the diagnosis and prognosis of experimental acute and chronic kidney injuries. Biomolecules. 2020;10(7): 981.
1. 1995 1st Prize of DEBIO-CCRF CHINA PRIZE.
2. 1998 2nd Prize of CHINA SCIENCE AND TECHNOLOGY ADVANCED PRIZE.
3. 2004 3rd Prize of DEBIO-CCRF CHINA PRIZE.
